AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On May25, 2017, Akebia Therapeutics, Inc. (the Company) announced
that Bradley Maroni, M.D., who served as the Companys Senior Vice
President and Chief Medical Officer, has transitioned into a new
role with the Company as medical advisor, effective May22, 2017.
The Company greatly appreciates Dr.Maronis many contributions to
the development of vadadustat and is pleased that he will remain
with the Company. As of May22, 2017, Rita Jain, M.D. was
appointed Senior Vice President and Chief Medical Officer of the
|Item7.01||Regulation FD Disclosure.|
The information contained in this Item shall not be deemed filed
for any purpose, and shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Securities Exchange Act of 1934, as amended,
regardless of any general incorporation language in any such
On May25, 2017, the Company issued a press release announcing the
appointment of Rita Jain, M.D., as Senior Vice President and
Chief Medical Officer of the Company as of May22, 2017. A copy of
the press release is attached to this report as Exhibit 99.1.
|Item9.01||Financial Statements and Exhibits.|
|99.1||Press Release of Akebia Therapeutics, Inc. dated May25, 2017|
About AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA)
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients. AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA) Recent Trading Information
AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA) closed its last trading session 00.00 at 14.24 with 435,423 shares trading hands.